ArticleNPJ cardiovascular health2026
Short- and long-term outcomes of systemic semilunar valve replacement in neonates and infants.
Article in NPJ cardiovascular health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Systemic semilunar valve replacement in neonates and infants is rare and usually a last resort. We analyzed Pediatric Cardiac Care Consortium data for patients undergoing Ross, aortic valve replacement (AVR), or truncal valve replacement (TVR) from 1982-2011 across 35 centers, with mortality tracked via the US National Death Index through 2022. Among 167 patients, in-hospital mortality was 23% for Ross, 49% for AVR, and 52% for TVR. Twenty-five-year survival was 59%, 29%, and 41%, respectively. Neonatal age (vs. infant) was associated with increased in-hospital and long-term mortality (OR 2.5, 3.9, respectively), while higher surgical weight was protective (OR 0.67, 0.61 per kg, respectively). The earlier surgical era was associated with higher in-hospital mortality (OR 3.4). AVR had over threefold in-hospital and long-term mortality (OR 3.2, 3.4, respectively). These results highlight the historically high risk of systemic semilunar valve replacement in this population and the need for innovative surgical approaches.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.